1. Home
  2. BZFD vs RCEL Comparison

BZFD vs RCEL Comparison

Compare BZFD & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BuzzFeed Inc.

BZFD

BuzzFeed Inc.

HOLD

Current Price

$1.50

Market Cap

111.9M

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$3.93

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BZFD
RCEL
Founded
2006
N/A
Country
United States
United States
Employees
507
226
Industry
Movies/Entertainment
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.9M
126.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BZFD
RCEL
Price
$1.50
$3.93
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
979.3K
251.9K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.69
$17.17
Revenue Next Year
$108.06
$49.82
P/E Ratio
$292.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$3.22
52 Week High
$2.68
$7.12

Technical Indicators

Market Signals
Indicator
BZFD
RCEL
Relative Strength Index (RSI) 53.75 41.49
Support Level $0.67 $3.28
Resistance Level $1.77 $4.09
Average True Range (ATR) 0.14 0.22
MACD -0.02 -0.00
Stochastic Oscillator 57.89 33.83

Price Performance

Historical Comparison
BZFD
RCEL

About BZFD BuzzFeed Inc.

BuzzFeed Inc is a digital media company across pop culture, entertainment, shopping, food, and news, its brands drive conversation and inspire what audiences watch, read, and buy now and into the future. Its iconic, globally-loved brands include BuzzFeed, HuffPost, and Tasty. The company generates revenue from advertising, content, commerce, and other sources.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: